Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities. Despite an increasing collective effort to improve health inequalities, a multitude of disparities continue to affect cardiovascular outcomes. Am...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | American Journal of Preventive Cardiology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666667723000193 |
| _version_ | 1797869663234818048 |
|---|---|
| author | Apurva Khedagi Cara Hoke Michelle Kelsey Andrea Coviello W. Schuyler Jones Larry R. Jackson, II Manesh R Patel Rob W. McGarrah Neha J Pagidipati Nishant P. Shah |
| author_facet | Apurva Khedagi Cara Hoke Michelle Kelsey Andrea Coviello W. Schuyler Jones Larry R. Jackson, II Manesh R Patel Rob W. McGarrah Neha J Pagidipati Nishant P. Shah |
| author_sort | Apurva Khedagi |
| collection | DOAJ |
| description | Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities. Despite an increasing collective effort to improve health inequalities, a multitude of disparities continue to affect cardiovascular outcomes. Among the most prominent disparities within cardiovascular disease prevention are with the use and distribution of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists. Several landmark trials have demonstrated the efficacy of these novel agents, not only in cardiovascular disease prevention among those with diabetes, but also in heart failure and chronic kidney disease. However, the use of these agents remains limited by disparities in certain racial/ethnic, sex, and socioeconomic groups. This review works to highlight and understand these differences on the use and prescribing patterns of pivotal agents in cardiovascular disease prevention, SGLT-2 inhibitors and GLP-1 agonists. Our aim is to enrich understanding and to inspire efforts to end disparities in cardiovascular morbidity and mortality due to race, sex and income inequality. |
| first_indexed | 2024-04-10T00:15:06Z |
| format | Article |
| id | doaj.art-0c56833b0aa04ebf94cf6b81e37f08c5 |
| institution | Directory Open Access Journal |
| issn | 2666-6677 |
| language | English |
| last_indexed | 2024-04-10T00:15:06Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Preventive Cardiology |
| spelling | doaj.art-0c56833b0aa04ebf94cf6b81e37f08c52023-03-16T05:06:41ZengElsevierAmerican Journal of Preventive Cardiology2666-66772023-03-0113100477Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonistsApurva Khedagi0Cara Hoke1Michelle Kelsey2Andrea Coviello3W. Schuyler Jones4Larry R. Jackson, II5Manesh R Patel6Rob W. McGarrah7Neha J Pagidipati8Nishant P. Shah9Department of Medicine, Duke University School of Medicine, Durham, NCDivision of Cardiology, Duke University School of Medicine, Durham, NCDivision of Cardiology, Duke University School of Medicine, Durham, NCDivision of Endocrinology, Metabolism, and Nutrition, Duke University School of MedicineDivision of Cardiology, Duke University School of Medicine, Durham, NCDivision of Cardiology, Duke University School of Medicine, Durham, NCDivision of Cardiology, Duke University School of Medicine, Durham, NCDivision of Cardiology, Duke University School of Medicine, Durham, NCDivision of Cardiology, Duke University School of Medicine, Durham, NCDivision of Cardiology, Duke University School of Medicine, Durham, NC; Corresponding author at: 2301 Erwin Rd, Durham NC 27705Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities. Despite an increasing collective effort to improve health inequalities, a multitude of disparities continue to affect cardiovascular outcomes. Among the most prominent disparities within cardiovascular disease prevention are with the use and distribution of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists. Several landmark trials have demonstrated the efficacy of these novel agents, not only in cardiovascular disease prevention among those with diabetes, but also in heart failure and chronic kidney disease. However, the use of these agents remains limited by disparities in certain racial/ethnic, sex, and socioeconomic groups. This review works to highlight and understand these differences on the use and prescribing patterns of pivotal agents in cardiovascular disease prevention, SGLT-2 inhibitors and GLP-1 agonists. Our aim is to enrich understanding and to inspire efforts to end disparities in cardiovascular morbidity and mortality due to race, sex and income inequality.http://www.sciencedirect.com/science/article/pii/S2666667723000193DisparitiesPreventionHealth equitySGLT2iGLP1-RA |
| spellingShingle | Apurva Khedagi Cara Hoke Michelle Kelsey Andrea Coviello W. Schuyler Jones Larry R. Jackson, II Manesh R Patel Rob W. McGarrah Neha J Pagidipati Nishant P. Shah Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists American Journal of Preventive Cardiology Disparities Prevention Health equity SGLT2i GLP1-RA |
| title | Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists |
| title_full | Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists |
| title_fullStr | Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists |
| title_full_unstemmed | Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists |
| title_short | Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists |
| title_sort | call to action understanding the differences in the use of sglt 2 inhibitors and glp 1 receptor agonists |
| topic | Disparities Prevention Health equity SGLT2i GLP1-RA |
| url | http://www.sciencedirect.com/science/article/pii/S2666667723000193 |
| work_keys_str_mv | AT apurvakhedagi calltoactionunderstandingthedifferencesintheuseofsglt2inhibitorsandglp1receptoragonists AT carahoke calltoactionunderstandingthedifferencesintheuseofsglt2inhibitorsandglp1receptoragonists AT michellekelsey calltoactionunderstandingthedifferencesintheuseofsglt2inhibitorsandglp1receptoragonists AT andreacoviello calltoactionunderstandingthedifferencesintheuseofsglt2inhibitorsandglp1receptoragonists AT wschuylerjones calltoactionunderstandingthedifferencesintheuseofsglt2inhibitorsandglp1receptoragonists AT larryrjacksonii calltoactionunderstandingthedifferencesintheuseofsglt2inhibitorsandglp1receptoragonists AT maneshrpatel calltoactionunderstandingthedifferencesintheuseofsglt2inhibitorsandglp1receptoragonists AT robwmcgarrah calltoactionunderstandingthedifferencesintheuseofsglt2inhibitorsandglp1receptoragonists AT nehajpagidipati calltoactionunderstandingthedifferencesintheuseofsglt2inhibitorsandglp1receptoragonists AT nishantpshah calltoactionunderstandingthedifferencesintheuseofsglt2inhibitorsandglp1receptoragonists |